ArticleAmerican journal of cancer research2026

Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights.

Aysegul Merc Cetınkaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.